The new frontier of “stealth” beta cells

For decades, type 1 diabetes has been one of regenerative medicine’s toughest challenges. Today science has made enormous strides: it is possible to produce functional pancreatic beta cells in the laboratory from stem cells. But the real problem is no longer making them — it is keeping them alive after transplantation.

The patient’s immune system, in fact, represents a formidable obstacle. On one hand it recognizes transplanted cells as foreign, triggering rejection; on the other, it can reactivate the autoimmune response that caused the disease, quickly destroying the new cells as well.

So far, the only strategy to avoid this outcome has been lifelong treatment with immunosuppressive drugs. However, these therapies carry significant risks, including kidney toxicity, increased susceptibility to infections, and a higher cancer risk — side effects that often limit the overall benefits of the transplant.

A possible turning point comes from a 2025 study published in the New England Journal of Medicine, which opens radically new scenarios. The researchers developed an innovative approach: instead of “turning off” the immune system, they made the transplanted cells invisible to it.

At the heart of this strategy is genetic engineering applied to stem cells. Using editing technologies such as CRISPR-Cas9, scientists modified the beta cells to alter their molecular profile. In particular, they removed class I HLA proteins, which act like a cellular “identity card” and allow the immune system to distinguish self from non-self.
This modification, however, introduces a new problem: cells lacking HLA become easy targets for another component of immune defenses, Natural Killer cells. To overcome this obstacle, the researchers added protective signals — such as HLA-E or CD47, known as the “don’t-eat-me” signal — capable of inhibiting the innate immune response as well.

The result is a cell described as “stealth”: functional and precise both in regulating blood glucose and producing insulin, while being practically invisible to the immune system.

In the studied models, these cells produced striking results: they survived without any immunosuppressive therapy and maintained stable glycemic control over time. This approach could also make encapsulation devices — previously used to protect transplanted cells but often ineffective due to fibrosis or poor oxygenation — unnecessary.

Clinically and conceptually, this represents a true paradigm shift. It is no longer about weakening the body’s defenses, but about designing cells capable of coexisting with them.
If long-term studies confirm the safety of this technology — particularly the absence of adverse effects related to genetic editing — type 1 diabetes could shift from a chronic disease to a condition potentially curable with a single cellular infusion.

This is the beginning of a new era: that of an “invisible” medicine, in which tissue repair occurs without compromising the organism’s overall balance.

Editorial written by prof. Antonio Giordano